• Journal of Physiology & Pathology in Korean Medicine
• /
• v.20 no.6
• /
• pp.1742-1748
• /
• 2006

In order to establish the manifestational symptoms in men and women and highly frequent symptoms(HFS) of deficiency of Qi and blood(氣虛, 血虛), stagnation of Qi(氣滯), deficiency of Yin(陰虛), deficiency of Yang(陽虛), and, 546 questionaires were analyzed through Cronbach alpha value and Pearson's correlative efficient. Symptomatic differences of male and female specimens were as follows. HFS of Qi deficiency were similar in terms of inactivity like mental and physical fatigue, enervation in men and women. In blood deficiency, dizziness and light sleep were common in men and women, but mucosal symptoms of conjunctiva, lip, nail bed were more frequent in women than men. Emotional explosion was common in Qi stagnation, then women had more motivation-related symptoms than men. Inner heat was frequently arisen in Yin deficiency in both, and the heat was expressed more common in exterior and upper part in women but in interior abdominal part in men. In Yang deficiency, main symptoms of men were feeling coldness in peripheral, but Qi deficiency symptoms were more common in women former than coldness.

• Asian Pacific Journal of Cancer Prevention
• /
• v.15 no.19
• /
• pp.8495-8497
• /
• 2014

Purpose: To investigate whether it is safe to use leucogen tablets 60 mg three times per day (180 mg for a day) and whether this regimen could reduce the incidence of febrile neutropenia caused by chemotherapy. Methods: This prospectively designed study focused on the safety and effectiveness of leucogen tablets 60mg three times per day for a group of cancer patients during chemotherapy for mainly lung or gastric cancers. The tablets were administered from 5 days before until the termination of chemotherapy. Neutropenia and other healthcare encounters were defined as events and occurrence was estimated for comparison. Results: We identified 39 patients receiving leucogen tablets 60mg three times per day, including 11 with gastric, 12 with lung and 16 with other sites of cancer. The mean age was 65 (29-75) years and there were 27 male and 12 female patients. The mean duration of leucogen tablets intake was 59 days. Eighteen patients were treated with taxane-based, 4 with irinotecan-based and 17 with other chemotherapy. The incidence of febrile neutropenia was 0%. Twelve patients were found severe neutropenia (grade III/IV), and the duration of severe neutropenia (grade III/IV) was 5 days. Treatment-emergent adverse events were attributable to complications of myelosuppressive chemotherapy or the primary disease (i.e., alopecia, nausea, asthenia, neutropenia, and severe hepatic renal dysfunction). No chemotherapy was delayed and no treatment related death was observed. Conclusions: This study suggested that leucogen tablets 60mg three times per day (180mg for a day) are safe and could be effective for preventing febrile neutropenia in patients with chemotherapy.